Spruce Street Capital LP, along with co-Managing Partners Alex R. Rosen and Simon Basseyn, filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 11,213,455 ordinary shares of Entera Bio Ltd. as of September 30, 2026.
Arrowstreet Capital, Limited Partnership and its parent Arrowstreet Capital Holding LLC filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 8,490,896 common shares of Asana, Inc. as of September 30, 2026.
Arrowstreet Capital, Limited Partnership and Arrowstreet Capital Holding LLC filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 2,362,074 common shares of Dave & Buster's Entertainment, Inc. as of September 30, 2026.
Arrowstreet Capital, Limited Partnership and Arrowstreet Capital Holding LLC filed a Schedule 13G Amendment No. 1 with the SEC on November 13, 2026, disclosing a beneficial ownership position in Lovesac Co common shares as of September 30, 2026.
Karpus Management, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 1,723,675 shares of common stock in JAB Acquisition Corp I, representing 6.06% of the class, as of September 30, 2026.
CapitalG filed an amended Schedule 13G on November 13, 2026, disclosing beneficial ownership positions in Freshworks Inc. as of September 30, 2026, through multiple related Delaware entities.
Arrowstreet Capital, Limited Partnership and Arrowstreet Capital Holding LLC filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 17,344,813 common shares of Freshworks Inc. as of September 30, 2026.
Karpus Management, Inc. filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of preferred shares of Carlyle Credit Income Fund as of September 30, 2026.
Karpus Management, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,300,023 shares of common stock in Drugs Made In America Acquisition II Corp., representing 5.18% of the class as of September 30, 2026.
Amesite Inc. filed a Form 8-K on November 13, 2026, disclosing that it received a deficiency notification from Nasdaq on November 11, 2026, for failing to maintain the minimum bid price requirement for continued listing on The Nasdaq Capital Market.